ISRCTN96315193 https://doi.org/10.1186/ISRCTN96315193

Comparison of the effect of Erythropoietin, L-Carnitine and Erythropoietin plus L-Carnitine in correction of anemia in chronic haemodialysis patients

Submission date 07/08/2005	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 11/08/2005	**Overall study status** Completed	
Last Edited 25/09/2009	**Condition category** Urological and Genital Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Hamid Tayebi Khosroshahi

Contact details
Dialysis Center
Imam Hospital
Daneshgah Street
Tabriz
Iran
+98 411 3344339
drtayebikh@yahoo.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Acronym
Carnitine-Epo

Study objectives
Anemia in chronic haemodialysis patients is improved by administration of Erythropoietin or L-Carnitine or Erythropoietin plus L-Carnitine.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Chronic Renal Failure (End-Stage Renal Disease [ESRD])

Interventions
1. Administration of rHu-EPO 4000 IU/week, subcutaneously (SC) (2000 IU, twice weekly) for 3 months (N = 20)
2. Administration of L-Carnitine 500 mg/day, orally, for 3 months (N = 15)
3. Administration of rHu-EPO 4000 IU/week, SC PLUS L-Carnitine 500 mg/day, orally, for 3 months (N = 15)

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Erythropoietin, L-Carnitine

Primary outcome measure
Haemoglobin level

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/03/2003

Completion date
01/03/2005

Eligibility

Key inclusion criteria
1. Dialysis for more than 6 months
2. Hb less than 11 g/dl

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
50

Key exclusion criteria
1. Active infectious disease
2. Active bleeding disorders

Date of first enrolment
01/03/2003

Date of final enrolment
01/03/2005

Locations

Countries of recruitment

Iran

Study participating centre
Dialysis Center
Tabriz
Iran

Sponsor information

Organisation
Tabriz University of Medical Sciences (Iran)

Sponsor details
Daneshgah Street
Tabriz
Iran

Sponsor type
University/education

Website
http://www.tbzmed.ac.ir

ROR
https://ror.org/04krpx645

Funder(s)

Funder type
University/education

Funder Name
Tabriz University of Medical Sciences (Iran)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration